DSpace university logo mark
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 030 医学部 > 030 学術雑誌論文 >

Delays in Neurological Drug Development in Japan

ファイル 記述 サイズフォーマット
IntMed50_1565.pdf122.8 kBAdobe PDF本文ファイル

タイトル: Delays in Neurological Drug Development in Japan
著者: Shimazawa, Rumiko / Ikeda, Masayuki
発行日: 2011年 8月 1日
出版者: The Japanese Society of Internal Medicine / 日本内科学会
引用: Internal Medicine, 50(15), pp.1565-1568; 2011
抄録: Objective The lag in the approval and development of neurological drugs between Japan and other countries has been a major issue for patients with neurological diseases. The objective of this study was to analyze the factors contributing to the delay in the launching of neurological drugs in Japan. Methods We analyzed data from Japan and the US for the approval of 36 standard neurological drugs and examined the potential factors that may cause the delay of their launch. Results Of the 36 standard neurological drugs, all of which were approved in the US, only 21 were introduced in Japan from June 1999 to April 2010, whereas the other 15, whose indications were Alzheimer disease, epilepsy, migraine, multiple sclerosis, and Parkinson disease, remained unapproved. The US led Japan in the number of introductions (20 versus 1), with introductions in Japan occurring at a median of 87 months after introductions in the US. Japan's review time of new drug applications (23 months) could not explain this lag. In 15 of the 21 approved drugs, the application data package included overseas data. The mean review time of these 15 drugs was significantly shorter than that of the other 6 drugs without overseas data. The maximum daily doses of 7 of the drugs were higher in the US than in Japan. Conclusion These results show that there is still a large gap between Japan and the US with regard to access to standard neurological drugs, despite several important reforms in the Japanese drug approval system.
キーワード: Clinical trials / Drug approval / Food and drug administration / International conference on har-monisation of technical requirements for registration of pharmaceuticals for human use (ICH)
URI: http://hdl.handle.net/10069/25855
ISSN: 09182918
DOI: 10.2169/internalmedicine.50.5061
権利: Copyright (c) 2011 by The Japanese Society of Internal Medicine
資料タイプ: Journal Article
原稿種類: publisher
出現コレクション:030 学術雑誌論文

引用URI : http://hdl.handle.net/10069/25855



Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace